Gene · 3062
Papers901
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 901
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Beyond traditional sleeping pills: safety, efficacy and multidisease potential of three approved orexin receptor antagonists. | Front Psychiatry | 2026 | 42683191 | PubTator, text mining | PubMed |
| Research Progress and Future Perspectives of Orexin Receptor Antagonists in Insomnia Therapy. | Molecules | 2026 | 42653878 | PubTator, text mining | PubMed |
| Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial. | Lancet Neurol | 2026 | 42636845 | PubTator, text mining | PubMed |
| Oveporexton: The first-in-class orexin receptor 2 (OX2R) agonist approved for treatment of narcolepsy type 1 (NT1). | Drug Discov Ther | 2026 | 42618292 | PubTator, text mining | PubMed |
| The orexin system as a pharmacological target in inflammation: peripheral mechanisms and safety implications. | Front Pharmacol | 2026 | 42609337 | PubTator, text mining | PubMed |
| Probing chemical space and conformational changes for subtype-selective orexin receptor antagonists. | RSC Med Chem | 2026 | 42592024 | PubTator, text mining | PubMed |
| Recent Advances and Emerging Pharmacotherapeutic Approaches for Central Hypersomnolence Disorders. | Clin Pharmacol | 2026 | 42583265 | PubTator, text mining | PubMed |
| Targeting Orexin 2 Receptors in Idiopathic Hypersomnia and Narcolepsy: A Randomised Phase 1b Proof-Of-Concept Study of Alixorexton. | J Sleep Res | 2026 | 42551881 | PubTator, text mining | PubMed |
| Lateral hypothalamic orexinergic neurons as central mediators of pain modulation and non-pharmacological analgesia. | Front Pharmacol | 2026 | 42460012 | PubTator, text mining | PubMed |
| The orexinergic system in the retina: Expression and physiological impact-A review of the literature. | Front Neuroendocrinol | 2026 | 42150720 | PubTator, text mining | PubMed |
| Identifying novel gene dysregulation associated with opioid overdose death: a meta-analysis of differential gene expression in human prefrontal cortex. | Transl Psychiatry | 2026 | 42103735 | PubTator, text mining | PubMed |
| Structural insights into the binding mode of the hypnotic drug vornorexant to orexin receptors. | Acta Crystallogr F Struct Biol Commun | 2026 | 42059114 | PubTator, text mining | PubMed |
| Physiological significance of autocrine orexinergic signaling in extra-hypothalamic tissues. | Physiol Rep | 2026 | 42033055 | PubTator, text mining | PubMed |
| Neuroendocrine Control of the Testis: Focus on Orexinergic Modulation of Spermatogenesis. | J Comp Neurol | 2026 | 41980893 | PubTator, text mining | PubMed |
| Hypothalamic Orexin Input to the Medial Amygdala Links Vigilance to Arousal. | bioRxiv | 2026 | 41959382 | PubTator, text mining | PubMed |
| When dreams feel real: the MÖBIUS model. | Commun Biol | 2026 | 41872455 | PubTator, text mining | PubMed |
Safety, tolerability, and preliminary efficacy of seltorexant versus quetiapine extended release as adjunctive therapy in major depressive disorder: a randomized, flexible-dose, 6-month, parallel-group, exploratory study. | Int J Neuropsychopharmacol | 2026 | 41795948 | PubTator, text mining | PubMed |
| Health risk analysis of micro-and nanoplastic exposure via the microbiota-gut-brain axis. | Front Immunol | 2026 | 41789083 | PubTator, text mining | PubMed |
| Association between genetic polymorphisms in circadian cycle genes (PER2, PER3, and HCRTR2) and Attention Deficit Hyperactivity Disorder (ADHD). | Chronobiol Int | 2026 | 41787892 | PubTator, text mining | PubMed |
| Orexin signaling across the female lifespan: developmental, reproductive, and aging perspectives from humans and animal models. | Front Neuroendocrinol | 2026 | 41690524 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3062/papers